Exec Summary: The HealthTech IPO market is expected to recover in the summer of 2024 with a number of factors now starting to build and...

Private equity firms have traditionally focused on investing in large, high-growth healthcare technology companies. However, there is a growing opportunity for private equity firms to tap into the midtier of the healthtech landscape. These midtier companies have demonstrated a proof of concept, have won flagship customers, and are consistently profitable. However, they are unlikely to reach billion-dollar valuations. This makes them attractive targets for private equity fi

Exec Summary: HealthTech is defined by the World Health Organisation (WHO) as ‘the application of organised knowledge and skills in the...

Exec Summary: The average revenue multiple for HealthTech companies in 2023 is 4.5x. This is down from 6.5x in 2022, but still higher...

Exec Summary: There are a number of reasons why the Teladoc Livongo merger did not work. Some of the most notable reasons include: The...

IBM's Watson was once heralded as the future of healthcare - what went wrong? Exec Summary: IBM's Watson was once heralded as the future...

What exactly is patient engagement? Patient engagement refers to the active involvement of patients in their own healthcare. It involves...

On the 10th Floor of a nondescript building at Columbia University, test subjects with electrodes attached to their heads watch a...

There is a new race in Silicon Valley involving Artificial Intelligence and no it's not HealthTech, FinTech, Voice Commerce or involve...

Should NHS Doctors charge for patient appointments? Faced with an ageing population and increased demand from diabetic and asthmatic...

Introduction to NeuroPace NeuroPace is an innovative medical device company dedicated to improving quality of life for individuals with...